CTKB at a glance
Cytek Biosciences, Inc. (CTKB, SEC CIK 1831915) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Cytek Biosciences, Inc. (CTKB) shares worth $253.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $201.5M
- +0.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $253.2M · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $53.2M, up 2% YoY from $52.3M, driven by service revenue $16.1M, up 13%
- Gross margin 59% vs 53% YoY, product margin 61% vs 53%, service margin 53% vs 51%
- Best performer: service revenue $16.1M, up $1.9M; weakest: product revenue $37.2M, down $1.0M
- Cash, equivalents, restricted cash and marketable securities $256.3M vs $261.5M at December 31, 2025; operating cash used $5.8M
- Near-term headwinds: biotech funding constraints, tariffs, export controls and potential NIH policy impacts on academic demand
Risk Factors
- New export-control risk: January 15, 2025 U.S. license requirements now cover certain flow cytometers and cell sorters exported to China
- Updated trade risk: Singapore and China tariff rates increased from 10% to 12.5%, potentially raising manufacturing costs
- New cybersecurity exposure: November 2025 security incident affected employee personal information
- Near-term demand risk: academic and government institutions generated 46% of revenue in Q3 2026, increasing exposure to NIH funding reductions
- Liquidity risk: existing cash expected to fund operating expenses for at least 12 months from the filing date
AI summary of the CTKB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Cytek announced financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details
Item EX-99.1: Item EX-99.1
- Q3 revenue $53.2M, up 2%, with U.S. revenue up 12% and high-end instrument revenue up 11%
- Recurring revenue $19.1M, reaching 36% of trailing-12-month revenue versus 33% previously, improving business visibility
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- A&R Bylaws effective September 23, 2026, adopted unanimously by the board
- Expanded disclosure, ownership, solicitation and certification requirements for stockholder proposals and director nominees
Item 8.01: Other Events
- Jury verdict favored Cytek on three of four asserted Beckman Coulter patent claims
- $20 million lost-profit award and $36.11 million royalty award for one claim
Item 7.01: Regulation FD Disclosure
- Jury verdict in Beckman Coulter patent infringement action, decided in the U.S. District Court for Delaware
- Litigation outcome creates potential intellectual property, product availability and financial exposure for Cytek
AI summaries of CTKB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CTKB
Don't miss the next CTKB filing
- Alerts as it files. A push when CTKB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CTKB, by share count.
- Ask anything. An AI agent that reads every CTKB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| McCombe William D. | M | Nov 18, 2026 | 6,320 | - |
| McCombe William D. | F | Nov 18, 2026 | 5,401 | $5.92 |
| McCombe William D. | M | Nov 18, 2026 | 13,051 | - |
| McCombe William D. | F | Nov 18, 2026 | 2,127 | $5.92 |
| McCombe William D. | F | Nov 18, 2026 | 4,392 | $5.92 |
| McCombe William D. | M | Nov 18, 2026 | 16,049 | - |
| MUIR GLENN P | M | Nov 18, 2026 | 4,629 | - |
| MUIR GLENN P | M | Nov 18, 2026 | 4,629 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $193.0M | $200.5M | $201.5M |
| Gross Profit | - | $111.1M | $104.5M |
| Operating Income | - | -$20.5M | -$40.4M |
| Net Income | - | -$6.0M | -$66.5M |
| Gross Margin | - | 55.4% | 51.8% |
| Op. Margin | - | -10.2% | -20.0% |
| Net Margin | - | -3.0% | -33.0% |
| Balance Sheet | |||
| Total Assets | $494.5M | $499.5M | $461.5M |
| Equity | $393.1M | $395.7M | $341.7M |
| ROE | - | -1.5% | -19.5% |
| Cash Flow | |||
| Operating CF | - | $25.4M | -$4.7M |
| CapEx | $4.6M | $3.5M | $4.1M |
Source: XBRL data in Cytek Biosciences, Inc. (CTKB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CTKB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $253.2M |
| Q2 2026 | 28 | $177.5M |
| Q1 2026 | 30 | $211.1M |
| Q4 2025 | 28 | $233.3M |
| Q3 2025 | 28 | $153.1M |
| Q2 2025 | 26 | $145.4M |
| Q1 2025 | 24 | $105.2M |
| Q4 2024 | 21 | $154.8M |
- BlackRock+2.61M (+27%)
- Two Sigma Investments+951.2K (+565%)
- D.E. Shaw & Co+569.4K (+85%)
- AQR Capital Management+505.5K (+62%)
- Bank of America Corp+303.4K (+23%)
- Millennium Management−2.06M (-22%)
- Wells Fargo & Co−78.2K (-76%)
- Vanguard Capital Management LLC−52.5K (-1%)
- Dimensional Fund Advisors−48.8K (-2%)
- Renaissance Technologies LLC−34.5K (-5%)
- M&T Bank+13.1K
- FMR LLC (Fidelity)−504.4K
- Franklin Resources−156.1K
- Ameriprise Financial−14.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CTKB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 4, 2026 | - | - | |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
CTKB SEC filings: frequently asked questions
Which institutions hold CTKB stock?
As of September 30, 2026, the largest Cytek Biosciences, Inc. (CTKB) holders among the 13F filers tracked by SignalX were BlackRock ($72.6 million), Millennium Management ($43.4 million), Vanguard Capital Management LLC ($29.1 million), Dimensional Fund Advisors ($15.3 million), State Street Corp ($15.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CTKB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Cytek Biosciences, Inc. (CTKB) reported revenue of $201.5 million (up 0.5% from FY2024) and a net loss of $66.5 million. The figures come from the XBRL data in the 10-K.
What did CTKB report in its latest 8-K?
Cytek Biosciences, Inc. (CTKB) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Cytek announced financial results for the quarter ended September 30, 2026.
What are the latest CTKB SEC filings?
Cytek Biosciences, Inc. (CTKB) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 20, 2026.
What is CTKB's SEC CIK number?
Cytek Biosciences, Inc. (CTKB)'s SEC Central Index Key (CIK) is 1831915. EDGAR lists every CTKB filing under that number.
Ask anything about CTKB
The research agent reads CTKB's filings, financials, insider trades and 13F holders, then answers with sources.